Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease
Cash and investment balance of $491.5 million as of March 31, 2026 expected to provide runway into early 2029
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
"We had another quarter of solid execution for our two global Phase 3 programs in generalized myasthenia gravis and primary Sjögren's disease, both of which are progressing as planned," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. "Encouragingly, clinician feedback this quarter points to a shift in myasthenia gravis treatment toward broader, more durable disease control through upstream B-cell modulation and targeting multiple pathogenic immunoglobulins, which are central to the BAFF/APRIL mechanism. While efficacy benchmarks in myasthenia gravis are well established, many physicians see the potential for this approach moving earlier in the treatment paradigm, given its potential to change the disease trajectory. Our conviction in telitacicept continues to grow, and we believe it has the potential to become a foundational therapy in B-cell driven autoimmune diseases."
Program Highlights
Telitacicept: a potential best- and first-in-class dual BAFF/APRIL inhibitor in development for generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD)
Generalized Myasthenia Gravis
UPSTREAM MG
Enrollment ongoing in global randomized, double-blind, placebo-controlled Phase 3 registrational trial with an open-label extension assessing the efficacy and safety of telitacicept in gMG
Topline data anticipated in 1H 2027
Primary Sjögren's Disease
UPSTREAM SjD
Enrollment ongoing in global randomized, double-blind, placebo-controlled Phase 3 registrational trial assessing the efficacy and safety of telitacicept in SjD
First Quarter 2026 Financial Results
